Holen Sie sich die Stockscreener-App
9.265
6.22%
-0.535
Schlusskurs vom Vortag:
$9.80
Offen:
$9.77
24-Stunden-Volumen:
1.15M
Relative Volume:
0.44
Marktkapitalisierung:
$1.38B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-738.82M
KGV:
-1.3311
EPS:
-6.9602
Netto-Cashflow:
$-610.15M
1W Leistung:
+13.60%
1M Leistung:
-7.36%
6M Leistung:
-42.13%
1J Leistung:
-50.56%
1-Tages-Spanne:
$9.00
$9.95
1-Wochen-Bereich:
$8.19
$10.16
52-Wochen-Spanne:
$7.48
$24.06
Biohaven Ltd Stock (BHVN) Company Profile
Firmenname
Biohaven Ltd
Sektor
Branche
Telefon
203-404-0410
Adresse
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
9.205 | 1.47B | 0 | -738.82M | -610.15M | -6.9602 |
VRTX
Vertex Pharmaceuticals Inc
|
433.89 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.12 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.85 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.40 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.62 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-06 | Eingeleitet | Goldman | Buy |
| 2026-01-21 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | Herabstufung | UBS | Buy → Neutral |
| 2025-11-06 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-09-17 | Eingeleitet | Citigroup | Buy |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-05-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-09-16 | Eingeleitet | Jefferies | Buy |
| 2024-09-04 | Eingeleitet | Bernstein | Outperform |
| 2024-07-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2023-12-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-01-24 | Eingeleitet | SVB Securities | Outperform |
| 2023-01-04 | Eingeleitet | JP Morgan | Overweight |
| 2022-12-02 | Eingeleitet | BTIG Research | Buy |
| 2022-10-26 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-05-11 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-08-10 | Herabstufung | UBS | Buy → Neutral |
| 2021-08-03 | Bestätigt | Canaccord Genuity | Buy |
| 2021-03-11 | Eingeleitet | UBS | Buy |
| 2020-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-17 | Eingeleitet | Cowen | Outperform |
| 2020-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Outperform |
| 2019-06-25 | Bestätigt | Canaccord Genuity | Buy |
| 2019-05-06 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | Bestätigt | Needham | Buy |
| 2018-07-03 | Bestätigt | Needham | Buy |
| 2018-07-02 | Bestätigt | Needham | Buy |
| 2018-04-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-02-22 | Bestätigt | Canaccord Genuity | Buy |
| 2017-12-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-10-03 | Bestätigt | Needham | Buy |
Alle ansehen
Biohaven Ltd Aktie (BHVN) Neueste Nachrichten
Aug Spikes: What is the long term forecast for Biohaven Ltd stock2026 Update & Consistent Profit Trade Alerts - baoquankhu1.vn
BHVN PE Ratio & Valuation, Is BHVN Overvalued - Intellectia AI
BHVN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart.com
Why Biohaven (BHVN) Is Up 11.7% After Fully Enrolling Its Phase 2 Obesity Drug Trial - Sahm
Biohaven Ltd. (BHVN) stock price, news, quote and history - Yahoo Finance UK
Citigroup Forecasts Strong Price Appreciation for Biohaven (NYSE:BHVN) Stock - MarketBeat
Citi Maintains Biohaven(BHVN.US) With Buy Rating, Raises Target Price to $17 - Moomoo
BHVN SEC FilingsBiohaven 10-K, 10-Q, 8-K Forms - Stock Titan
Biohaven Ltd. (BHVN) Stock Price, News, Quote & History - Yahoo! Finance Canada
BHVN Stock Price, Quote & Chart | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
Biohaven (NYSE:BHVN) Shares Up 10.5%Here's Why - MarketBeat
Biohaven Jumps 10.9% Amid Robust Intraday Rally—What’s Driving This Upswing? - Bitget
Biohaven (BHVN) Fuels Confidence With Encouraging Azetukalner Data - Insider Monkey
Biohaven Ltd. (BHVN)’s BHV-1400 Cuts Disease Antibody by 81% in IgA Nephropathy - MSN
Aug Final Week: Can Biohaven Ltd stock outperform in a bear market2026 Price Targets & Smart Investment Allocation Tips - baoquankhu1.vn
Investment Recap: Can Biohaven Ltd deliver alpha2026 Update & Accurate Intraday Trade Tips - baoquankhu1.vn
Biohaven (BHVN) completes enrollment in phase 2 obesity study of taldefgrobep alfa - MSN
Breakout Zone: Can Biohaven Ltd be recession proofDip Buying & Weekly High Return Stock Forecasts - baoquankhu1.vn
Can Biohaven (BHVN) Redefine Obesity Treatment By Targeting Lean Mass Preservation With Taldefgrobep? - Yahoo Finance
Gains Recap: How does Biohaven Ltd score in quality rankingsLayoff News & Detailed Earnings Play Alerts - baoquankhu1.vn
Market Pulse: What are analysts price targets for Biohaven Ltd2026 Volatility Report & Risk Managed Trade Strategies - baoquankhu1.vn
The Technical Signals Behind (BHVN) That Institutions Follow - Stock Traders Daily
Biohaven shares edge higher after completing enrollment in obesity drug trial - MSN
Biohaven (BHVN) Completes Enrollment in Phase 2 Obesity Study of Taldefgrobep Alfa - Insider Monkey
Biohaven (NYSE:BHVN) Trading 6.2% HigherHere's Why - MarketBeat
Can Biohaven (BHVN) Redefine Obesity Treatment By Prioritizing Muscle Preservation Over Pure Weight Loss? - simplywall.st
JPMorgan Chase & Co. Sells 1,236,587 Shares of Biohaven Ltd. $BHVN - marketbeat.com
Assessing Biohaven (BHVN) Valuation As Losses Persist And Price To Book Hits 25x - simplywall.st
Biohaven Shares Drop 70%, Yet a Fund’s Fresh $6 Million Investment Hints at Possible Recovery - Bitget
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - The Motley Fool
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - The Motley Fool
Movement Recap: What is the long term forecast for Biohaven Ltd stockGDP Growth & Weekly High Return Stock Forecasts - baoquankhu1.vn
Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Biohaven’s robust cash reserves and unique degrader strategy ignite a strong value opportunity, with crucial 2026 clinical trials approaching - Bitget
Biohaven's 2026 Pivotal Trial Countdown: Can Capital Discipline Unlock a High-Risk, High-Reward Moat? - Bitget
DAFNA Capital Management Increases Biohaven Ltd. Investment in 2025News and Statistics - IndexBox
Biohaven Ltd.: Fundamental Analysis and Financial Ratings | BHVN34 | BRBHVNBDR001 - marketscreener.com
Biohaven completes enrollment in obesity drug trial By Investing.com - Investing.com India
Biohaven (NASDAQ: BHVN) director reports gifting 34,684 shares, adds family trust - Stock Titan
Risk Off: What is the long term forecast for Biohaven Ltd stock2026 Market WrapUp & Precise Swing Trade Alerts - baoquankhu1.vn
Biohaven Therapeutics discloses prodrugs of betahistine - BioWorld MedTech
Biohaven Ltd. Completes Enrollment In Phase 2 Obesity Study With Taldefgrobep Alfa - marketscreener.com
Biohaven completes enrollment in obesity drug trial - Investing.com
Biohaven stock rises as obesity trial completes enrollment - Investing.com UK
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment - PR Newswire
Biohaven has completed enrollment for its obesity study—However, the market still hasn't factored in the potential risk of the trial not succeeding - Bitget
Finanzdaten der Biohaven Ltd-Aktie (BHVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):